Jose Duran-Moreno1, Katerina Kampoli1, Emmanouil I Kapetanakis2, Maria Mademli3, Nektarios Koufopoulos4, Periklis G Foukas4, Kostas Kostopanagiotou2, Periklis Tomos2, Anna Koumarianou5. 1. Hematology Oncology Unit, Fourth Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece. 2. Department of Thoracic Surgery, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece. 3. Second Department of Radiology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece. 4. Second Department of Pathology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece. 5. Hematology Oncology Unit, Fourth Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece akoumari@yahoo.com.
Abstract
BACKGROUND: Pericardial synovial sarcomas (PSS) are very rare tumors, with dismal prognosis and limited data. We describe the clinical features and identify prognostic factors of primary PSS. CASE REPORT: We describe the case of a 56-year-old male patient with PSS managed by the multidisciplinary team of thoracic oncology. The therapeutic plan comprised surgery, chemotherapy, stereotactic radiosurgery and targeted therapy, with excellent results. MATERIALS AND METHODS: Data from 37 cases reported in English during the past 20 years were gathered and analyzed. PSS was found to occur at a mean age of 36±17.082 (range=13-67) years. Survival analysis was performed on 20 cases with follow-up of at least 6 months. CONCLUSION: Only complete resection of the tumor seems to be an independent prognostic factor. To our knowledge, this is the first report on the safety and effectivity of pazopanib in PSS and may provide guidance for similar cases in the future. Copyright
BACKGROUND:Pericardial synovial sarcomas (PSS) are very rare tumors, with dismal prognosis and limited data. We describe the clinical features and identify prognostic factors of primary PSS. CASE REPORT: We describe the case of a 56-year-old male patient with PSS managed by the multidisciplinary team of thoracic oncology. The therapeutic plan comprised surgery, chemotherapy, stereotactic radiosurgery and targeted therapy, with excellent results. MATERIALS AND METHODS: Data from 37 cases reported in English during the past 20 years were gathered and analyzed. PSS was found to occur at a mean age of 36±17.082 (range=13-67) years. Survival analysis was performed on 20 cases with follow-up of at least 6 months. CONCLUSION: Only complete resection of the tumor seems to be an independent prognostic factor. To our knowledge, this is the first report on the safety and effectivity of pazopanib in PSS and may provide guidance for similar cases in the future. Copyright
Authors: Lawrence H Schwartz; Lesley Seymour; Saskia Litière; Robert Ford; Stephen Gwyther; Sumithra Mandrekar; Lalitha Shankar; Jan Bogaerts; Alice Chen; Janet Dancey; Wendy Hayes; F Stephen Hodi; Otto S Hoekstra; Erich P Huang; Nancy Lin; Yan Liu; Patrick Therasse; Jedd D Wolchok; Elisabeth de Vries Journal: Eur J Cancer Date: 2016-05-26 Impact factor: 9.162
Authors: Yong Luo; Ke Gong; Ting Xie; Ruilin Liu; Hui Guo; Lei Wang; Zhiping Tan; Shi Jun Hu; Yifeng Yang; Li Xie Journal: Front Cardiovasc Med Date: 2022-01-27